Χώρα: Ηνωμένο Βασίλειο
Γλώσσα: Αγγλικά
Πηγή: MHRA (Medicines & Healthcare Products Regulatory Agency)
Azathioprine
Teva UK Ltd
L04AX01
Azathioprine
25mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 08020100; GTIN: 5017007398912 5017007314639
Sandoz Business use only Page 1 of 8 1.3.1 spc-label-pl - common-pl-001 - 46 (NL/H/0326-0327-0328/001 changeID 165986) 20180827 AZATHIOPRINE 25 MG FILM-COATED TABLET 800-0036.00 PACKAGE LEAFLET: INFORMATION FOR THE PATIENT [NATIONALLY APPROVED NAME] 25 MG TABLETS Azathioprine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What [Nationally approved name] are and what they are used for 2. What you need to know before you take [Nationally approved name] 3. How to take [Nationally approved name] 4. Possible side effects 5. How to store [Nationally approved name] 6. Contents of the pack and other information 1. WHAT [NATIONALLY APPROVED NAME] ARE AND WHAT THEY ARE USED FOR [Nationally approved name] belong to a group of medicines called immunosuppressives. This means that they reduce the strength of your immune system. Immunosuppressive medicines are sometimes necessary to help your body accept an organ transplant, or to treat some diseases where your immune system is reacting against your own body (autoimmune diseases, such as rheumatoid arthritis). 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE [NATIONALLY APPROVED NAME] DO NOT TAKE [NATIONALLY APPROVED NAME]: if you are allergic to azathioprine or any of the other ingredients of this medicine (listed in section 6) if you are allergic to mercaptopurine. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before taking [Nationally approved name]: if you suffer from the condition known as Lesch-Nyhan Syndrome. This is a rare condition that r Διαβάστε το πλήρες έγγραφο
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Azathioprine 25 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 25 mg azathioprine. Excipient with known effect: Each tablet contains 45 mg of lactose (as lactose monohydrate) For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. White to yellowish-white, round, biconvex film-coated tablet of diameter 6.0-6.4mm and height of 3.1-3.7mm,with no score-line. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Azathioprine is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. Therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. Azathioprine, combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated to enhance the survival of organ transplants, such as renal transplants, cardiac transplants, and hepatic transplants. It also reduces the corticosteroid requirements of renal transplant recipients. Azathioprine is indicated for the treatment of moderate to severe inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis) in patients in whom corticosteroid therapy is required, in patients who cannot tolerate corticosteroid therapy, or in patients whose disease is refractory to other standard first line therapy. Azathioprine either alone or more usually in combination with corticosteroids and/or other medicinal products and procedures, has been used with clinical benefit (which may include reduction of dosage or discontinuation of corticosteroids) in a proportion of patients suffering from the following: - Severe active rheumatoid arthritis; - Systemic lupus erythematosus; - Dermatomyositis and polymyositis; - Auto-immune chronic active he Διαβάστε το πλήρες έγγραφο